EP2268254A1 - Procédé et trousse permettant d'administrer un traitement endodontique régénératif - Google Patents

Procédé et trousse permettant d'administrer un traitement endodontique régénératif

Info

Publication number
EP2268254A1
EP2268254A1 EP08861918A EP08861918A EP2268254A1 EP 2268254 A1 EP2268254 A1 EP 2268254A1 EP 08861918 A EP08861918 A EP 08861918A EP 08861918 A EP08861918 A EP 08861918A EP 2268254 A1 EP2268254 A1 EP 2268254A1
Authority
EP
European Patent Office
Prior art keywords
cells
kit
scaffold
dental pulp
root canal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08861918A
Other languages
German (de)
English (en)
Other versions
EP2268254A4 (fr
Inventor
Peter E. Murray
Franklin Garcia-Godoy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nova Southeastern University
Original Assignee
Nova Southeastern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nova Southeastern University filed Critical Nova Southeastern University
Publication of EP2268254A1 publication Critical patent/EP2268254A1/fr
Publication of EP2268254A4 publication Critical patent/EP2268254A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/50—Preparations specially adapted for dental root treatment

Definitions

  • the present invention relates to the practice of endodontics, commonly known as root-canal therapy, which is a specialist sub-field of dentistry.
  • Embodiments of the invention are directed to methods and kits for use in endodontic procedures.
  • Root canal is the commonly used term for the main canals within the dentin of the tooth. These canals are part of the natural cavity within a tooth that consists of the dental pulp chamber. Root canals are filled with a highly vascularized, loose connective tissue known as dental pulp tissue.
  • Dental pulp tissue may become infected, diseased, and/or inflamed, generally due to dental decay or tooth fractures, thus allowing microorganisms (mostly bacteria from the oral flora or their byproducts) to access the pulp chamber or the root canals. Infected tissue is often removed by a surgical intervention known as endodontic therapy and commonly referred to as a "root canal.”
  • Regenerative medicine refers to the use of a combination of biomedical imaging, progenitor cells, three-dimensional scaffold materials, and suitable biochemical factors or gene therapy to improve or replace biological functions in an effort to effect the advancement of medicine.
  • the basis for regenerative medicine is the utilization of tissue engineering therapies.
  • regenerative medicine represents applications that repair or replace structural and functional tissues including bone, cartilage, and blood vessels, among other organs and tissues.
  • the principles of regenerative medicine can be applied to endodontic tissue engineering, specifically, through the regeneration and revascularization of dental pulp tissue.
  • the ability to regenerate and revascularize dental pulp tissue provides patients with a clear alternative to current root canal therapies, as well as obturation of the root canal with dental materials.
  • Embodiments of the present invention provide a novel method to remove unhealthy pulp tissue from inside the root canals of a tooth, and to replace it with new vascularized tissue created by regenerative endodontic treatment.
  • the present invention also provides, in some embodiments, novel kits for removing unhealthy pulp tissue from inside the root canals of a tooth, and replacing it with new vascularized tissue created by regenerative endodontic treatment.
  • Figure 1 Shows a schematic of regenerative endodontic treatment.
  • Figure 2 Shows a flow chart of an example of the methodology for regenerative endodontic treatment.
  • Figure 3 Shows a flow chart describing an example of a regenerative endodontic treatment kit of the present invention.
  • Figure 4 Shows the creation of replacement revascularized tissues inside root
  • Figure 5 Shows the biocompatibility measurements of regenerative endodontic treatment.
  • the survival, death, attachment, and proliferation of dental pulp stem cells (A) and other types of cells including periodontal stem cells (B) can be used to test biocompatibility, and cytotoxicity of the scaffolds, files/cleaning instruments, biomaterials, disinfectants, and medicaments to be used as part of regenerative endodontic treatment shown in Figures 1, 2 or 3.
  • A dental pulp stem cells
  • B periodontal stem cells
  • FIG. 1, 2 or 3 Prior to in vivo clinical or animal testing, these procedures may be tested using in vitro extracted teeth and cell culture techniques.
  • Figure 6 Shows the efficacy measurements of regenerative endodontic treatment.
  • the efficacy of regenerated tissues within the root canal of in vivo teeth can be measured using non-invasive methods such as Doppler measurements of blood flow and electrical pulp vitality testing. In the case of clinical trials, patients may be asked to rate the success of the treatment.
  • the teeth may also be extracted for assessment of tissue regeneration associated with the revascularized root canals. Alternatively, extracted teeth may be subject to various aspects of endodontic tissue regeneration to measure the in vitro efficacy of the regenerative endodontic procedures prior to their clinical or animal testing.
  • the measurement methods include cell survival assays, as well as adherence to root canal surfaces, using scanning/transmission electron microscopy, and histology.
  • the image below shows the efficacy testing of a collagen scaffold seeded with dental pulp stem cells to create a dental pulp construct implanted into a root canal following the removal of pulp tissues, and its disinfection.
  • Adherence was observed between the implanted scaffold containing stem cells and the root canal surface (A).
  • Stem cells remained attached to the scaffold for up to 14 days in culture (B).
  • the histology of the replacement pulp cells within the scaffold was found to be actively metabolizing (C) suggesting the construct was vital.
  • Figure 7 Shows the sourcing, banking and delivery of stem cells and scaffolds for use in regenerative endodontic treatment.
  • Figure 8 A dental pulp stem cell bank for regenerative endodontic treatment.
  • Figure 9 Shows cell repopulation and tissue regeneration within a revascularized tooth root canal containing a collagen scaffold.
  • Figure 10 Shows cell repopulation and tissue regeneration within a revascularized tooth root canal containing Pl 5 Pepgen.
  • Figure 11 Shows cell repopulation and tissue regeneration within a revascularized tooth root canal containing a blood clot.
  • Figure 12 Shows cell repopulation and tissue regeneration within the root canals of teeth following regenerative endodontic treatments.
  • Figure 13 Shows cell repopulation of revascularized root canals following regenerative endodontic treatments.
  • the present invention describes methods, compositions, devices and kits to disinfect, clean, and revascularize the root canals of in vivo, ex vivo, or re-implanted teeth, following the removal of unhealthy or necrotic pulp tissue.
  • the present invention may be used as a direct replacement or alternative to the use of gutta percha, mineral trioxide aggregate, and/or dental cements that are currently used as root canal obturation materials in endodontic treatment.
  • the present invention provides a method of removing unhealthy pulp tissue from inside the root canals of a tooth, and replacing it with new vascularized tissue created by regenerative endodontic treatment.
  • This method can include any or all of the following steps: (a) creating an access opening to the root canal system; (b) removing unhealthy or necrotic dental pulp tissue from the root canal system; (c) cleaning and disinfecting the root canal system; (d) causing blood to flow into the root canal system by instrumenting the apex; and (e) inserting into the root canal system a scaffold (e.g., rigid or injectable) that can have progenitor dental pulp cells and/or growth factors.
  • a scaffold e.g., rigid or injectable
  • root canal instrumentation means the controlled removal of dentin and pulp tissues using dental instruments, normally endodontic files and/or ultrasonic tips in combination with irrigating solutions (e.g., NaOCl) and optionally with smear layer removal agents (e.g, EDTA).
  • irrigating solutions e.g., NaOCl
  • smear layer removal agents e.g, EDTA
  • the methods described herein can include applying a postoperative sealant to the coronal and/or apical access to the root canal to help prevent infection.
  • Teeth are identified as requiring root canal treatment to remove unhealthy or necrotic pulp tissues.
  • the tooth can be anesthetized prior to surgery.
  • An opening is made through the crown or apex of the tooth to access the root canal.
  • An access preparation can also be made through the dentin to the root canal using a dental hand-piece and bur.
  • the unhealthy or necrotic dental pulp tissue is then removed from the root canals using, for example, a file, irrigating solutions, acids, chelating agents, and/or any suitable equivalent thereof.
  • the root canals are then disinfected following the removal of almost all of the necrotic pulp tissue by endodontic root canal therapy.
  • the methods described herein include revascularization.
  • Revascularization is a surgical procedure for the provision of a new, additional, or augmented blood supply to the root canal.
  • Revascularization has several advantages.
  • the procedure is technically simple and can be completed using currently available instruments and medicaments without expensive biotechnology.
  • the regeneration of tissue in root canal systems by a patient's own blood cells avoids the possibility of immune rejection and pathogen transmission from replacing the pulp with a tissue engineered construct.
  • enlargement of the apical foramen not only promotes vascularizaton but can also maintain initial cell viability via nutrient diffusion.
  • the root canal system is revascularized by establishing bleeding into the canal system via over-instrumentation.
  • instrumenting the tooth apex causes blood to flow into the root canal.
  • intracanal irrigants NaOCl and chlorhexidine
  • antibiotics e.g., a mixture of ciprofloxacin, metronidazole, and minocycline paste
  • Re-implantation of avulsed and/or necrotic teeth with an apical opening of approximately 1.1 mm can have a greater likelihood of revascularization.
  • Revascularization of necrotic pulps with fully formed (“closed") apices may require instrumenting the tooth apex to approximately 1-2 mm in apical diameter to allow systemic bleeding into root canal systems.
  • the methods of the present invention can involve the addition of progenitor cells, optionally, while implanting the scaffold described below into a patient.
  • Dental pulp contains a progenitor cell population referred to as pulp stem cells, or in the case of immature teeth, stem cells from human exfoliated deciduous teeth (SHED).
  • Pulp stem cells are also referred to as odontoblastoid cells because these cells appear to synthesize and secrete dentin matrix like the odontoblast cells they replace. Following severe pulp damage or mechanical or caries exposure, the odontoblasts are often irreversibly injured beneath the wound site.
  • Odontoblasts are post-mitotic terminally differentiated cells, and cannot proliferate to replace subjacent irreversibly-injured odontoblasts.
  • Pulp stem cells for the odontoblastoid cells are resident, undifferentiated mesenchymal cells. The origins of these cells may be related to the primary odontoblasts because during tooth development, only the neural crest derived cell population of the dental papilla is able to specifically respond to the basement membrane- mediated inductive signal for odontoblast differentiation. The ability of both young and old teeth to respond to injury by induction of reparative dentinogenesis suggests that a small population of competent pulp stem cells may exist within the dental pulp throughout life.
  • Progenitor cells can be identified and isolated from mixed cell populations by using, for example, four techniques: i) Staining the cells with specific antibody markers and using a flow cytometer in a process called fluorescent antibody cell sorting (FACS); ii) immuno-magnetic bead selection; iii) immuno-histochemical staining; and iv) physiological and histological criteria, including but not limited to, phenotype (appearance), chemotaxis, proliferation, differentiation and mineralizing activity. FACS together with the protein marker CD34 is widely used to separate human stem cells expressing CD34 from peripheral blood, umbilical cord blood, and cell cultures.
  • FACS fluorescent antibody cell sorting
  • progenitor cells Different types of progenitor cells often express different proteins on their membranes and are therefore not identified by the same progenitor cell protein marker.
  • the most studied dental progenitor cells are pulp stem cells. Human pulp stem cells express von Willebrand factor CD146, alpha-smooth muscle actin, and 3G5 proteins. Human pulp stem cells also have a fibroblast phenoptype, with specific proliferation, differentiation and mineralizing activity patterns.
  • progenitor dental pulp cells from autologous (the patient's own) cells are derived from a buccal mucosal biopsy.
  • pulp stem cells are derived from an allogenic purified pulp stem cell line that is disease and pathogen-free.
  • the pulp stem cells are derived from xenogenic (animal) pulp stem cells that have been grown in the laboratory.
  • progenitor cells from autogenous cells are derived from umbilical cord stem cells that have been cryogenically stored after birth.
  • Autogenous stem cells are relatively easy to harvest, easy to deliver by syringe, and the cells have the potential to induce new pulp regeneration.
  • the use of autogenous human pulp stem cell line is also advantageous because the patient does not need to provide their own cells through a biopsy. Moreover, purification and expansion of cell number would permit collection of smaller tissue biopsies — although the patient will still have to wait some time before the cells have been purified and/or expanded in number.
  • progenitor dental pulp cells are sourced from extracted or in situ deciduous or permanent teeth, and surrounding oral tissues.
  • the progenitor dental pulp cells can be collected from dental tissues including, but not limited to, dental pulp, periodontal, apical papilla or cementum tissues, by growing the cells in cell culture or using a cell sorting technique by stem cell markers.
  • the dental tissues are prepared for cell culture by enzymatic digestion, or disaggregated by mechanical instrumentation. The tissues are then dried onto cell culture plates, or immobilized under a solid glass or plastic cover-slip.
  • the tissues are submerged in a nutrient cell culture media, with or without bovine serum or synthetic substitute at a concentration, for example, of between 1 and 50%, and maintained in an incubator at a temperature, for example, of 37°C and a 1-10% CO 2 atmosphere.
  • the cell cultures in some embodiments, can optionally be treated with a number of additives as needed.
  • antibiotics and antifungal agents can be added to avoid infection of the cell cultures.
  • Vitamin C and L-glutamine can also be added to the culture media to provide essential proteins.
  • Bioactive molecules for example growth factors, can also be added to the culture media.
  • the cells After the cells have reached confluence they can be harvested from the culture dishes using, for example, trypsinization with or without EDTA, centrifuged, and re- suspended in cell culture plates with cell culture media.
  • the harvested cells may be suspended in freezing media, for example, comprising 10% DMSO in bovine serum, or synthetic serum, or cell culture media.
  • the cells in the freezing media can be slowly frozen in small aliquots, and placed into ultra-low temperature freezers for storage, or placed and stored in a tank containing liquid nitrogen.
  • each aliquot of cells is marked with a code to link them to the donor, or to identify any information about the donor.
  • the cells may be removed from storage at any time and grown in culture to ensure the viability of the cells.
  • the frozen aliquots are thawed every year, or every few years.
  • the cells are removed from frozen storage, suspended in culture media, and maintained in an incubator until they reach confluence. If the cells are already in culture, they are grown until they reach confluence. The confluent cells are re- plated to expand the total numbers of cells.
  • they are harvested through, for example, trypsinization and seeded on three dimensional biomaterials commonly known as tissue engineering scaffolds.
  • progenitor dental pulp cells are organized into a three-dimensional scaffold that can support cell organization and vascularization. This can be accomplished using a porous polymer scaffold seeded with progenitor dental pulp cells to create a dental pulp construct.
  • the cells are seeded on the scaffolds and are immediately implanted into the oral tissue of humans or animals, or, in another embodiment, the cell and scaffold constructs may be maintained in cell culture for days, weeks, and even months prior to implantation into the oral tissues of humans or animals.
  • the tissue scaffolds can be created in uniform sizes, colors, and/or shapes.
  • the synthetic constructs may be created in a range of naturally occurring tooth sizes, tooth colors and tooth shapes.
  • the size, thickness and appearance of the tissues can be determined by the size, shape and properties of the tissue engineering scaffold.
  • the scaffold can be coated with one or more of the following: hydroxylapatite (hydroxyapatite); cell adhesion molecules; extracellular matrix proteoglycan matrix components such as heparin sulfate proteoglycans, chondroitin sulfate proteoglycans, keratin sulfate proteoglycans; or non-pro teogl yean matrix components such as laminin, hyaluronic acid, collagen, fibronectin, and elastin.
  • extracellular matrix proteoglycan matrix components such as heparin sulfate proteoglycans, chondroitin sulfate proteoglycans, keratin sulfate proteoglycans
  • non-pro teogl yean matrix components such as laminin, hyaluronic acid, collagen, fibronectin, and elastin.
  • the scaffold is further comprised of nutrients promoting cell survival and growth, as well as antibiotics to prevent any bacterial in-growth in the root canal systems.
  • the scaffold may exert essential mechanical and biological functions needed by a replacement tissue.
  • dentin chips may provide a matrix for progenitor dental pulp cell attachment and also serve as a reservoir of growth factors.
  • the scaffold is biodegradable so that it may be absorbed by the surrounding tissues without the necessity of surgical removal.
  • the scaffold has a high porosity and an adequate pore size to facilitate cell seeding and diffusion throughout the whole structure of both cells and nutrients.
  • the rate at which scaffold degradation occurs can, in some embodiments, coincide with the rate of tissue formation near the scaffold. In other words, while cells are fabricating their own natural matrix structure around themselves, the scaffold should be able to provide structural integrity. Likewise, around the time when the newly formed tissue has developed to the point where it can independently carry the mechanical load, the scaffold should begin to break down.
  • the scaffolds of the present invention can be made of natural or synthetic materials that are either biodegradable or permanent.
  • Common synthetic materials include, but are not limited to, gelatin, polylactic acid (PLA), polyglycolic acid (PGA), and polycaprolactone (PCL), which are all common polyester materials that degrade within the human body.
  • PLA polylactic acid
  • PGA polyglycolic acid
  • PCL polycaprolactone
  • Scaffolds may also be constructed from natural materials, including but not limited to several proteic materials such as collagen, calcium phosphate, fibrin, and polysaccharide materials like chitosan or glycosaminoglycans (GAGs). Most of these scaffold materials are biocompatible and biodegradable to allow new tissues to regenerate inside the root canal. However, certain scaffold materials such as polytetrafluoroethylene (PTFE) are permanent non-degradable scaffold materials and will remain in the root canal.
  • PTFE polytetrafluoroethylene
  • a rigid tissue engineering scaffold structure may assist with the organization and vascularization of progenitor dental pulp cells in the root canal system.
  • tissue engineered pulp tissue is administered in a soft three-dimensional scaffold matrix such as a polymer hydrogel, gelatin, and agar-based gels.
  • Hydrogels and other gel-based formulations are injectable scaffolds that can be delivered by syringe.
  • injectable scaffolds are noninvasive and easy to deliver into root canal systems.
  • the injectable scaffold is photopolymerizable, or able to form rigid structures once implanted into the desired tissue site.
  • the tissue constructs may be designed by computer software using data collected from radiographs, and/or magnetic resonance images, and/or micro-CT x-ray tomography to precisely fit a single or multiple recipient sites in a human or animal.
  • the three-dimensional scaffolds are surgically implanted into humans or animals, without seeding progenitor cells on these scaffolds in vitro or in situ prior to implantation.
  • the recipients of the scaffolds are given medicaments containing pharmaceutical compounds (e.g., drugs, biologies, or adjuvants) which activate and mobilize the host recipients own progenitor cells to colonize the scaffold and regenerate the lost, missing, diseased, or injured dental tissues.
  • pharmaceutical compounds e.g., drugs, biologies, or adjuvants
  • Another embodiment of the methods of the present invention includes providing effective therapies for stimulating revascularization and regeneration of tissue within the root canal. These methods can involve administering a growth factor to the patient or a compound capable of stimulating growth factor production.
  • dentin e.g., in a chip form
  • dentin contains many proteins capable of stimulating tissue responses. Once released, these growth factors can play key roles in signaling many of the events of tertiary dentinogenesis, a response of pulp-dentin repair.
  • Growth factors especially those of the transforming growth factor-beta (TGF ⁇ ) family, are important in cellular signaling for odontoblast differentiation and stimulation of dentin matrix secretion. These growth factors are secreted by odontoblasts and deposited within the dentin matrix where they remain protected in an active form through interaction with other components of the dentin matrix.
  • TGF ⁇ transforming growth factor-beta
  • BMP bone morphogenic proteins
  • Recombinant human BMP2 stimulates differentiation of adult pulp stem cells into an odontoblastoid morphology in culture.
  • TGF Bl-3 and BMP7 have been demonstrated in cultured tooth slices.
  • Recombinant BMP-2, -4, -7 induce formation of reparative dentin in vivo.
  • the application of recombinant human insulin-like growth factor- 1 together with collagen has been found to induce complete dentin bridging and tubular dentin formation. Accordingly, in some embodiments, a BMP can be administered as part of the methods described herein.
  • Another embodiment of the present invention includes the use of pharmaceutical compounds in the methods described herein to facilitate directional migration of progenitor cells.
  • Directional migration of progenitor cells or stem cells can be necessary for embryonic development as well as for homeostatic maintenance and repair of injured organs and tissues in adults.
  • progenitor cells in the absence of migration, the contribution of progenitor cells to the development of functional organs and tissues would not be possible, as all progenitor cells must migrate to sites where they are required to function.
  • Rho The Rho family of GTPases constitute a family of intracellular messengers that are regulated both by their location and state of activation. They exert important influences in almost all functions of the progenitor cell, including adherence and migration. For example, Rho exerts important effects on cellular contraction and detachment, while Rac exerts effects needed for directed migration of polarized cells. Cdc42 activates many of the same receptors as Rac, but its effects appear limited to those involving cellular morphology and lamillopodia development. Studies have demonstrated Rac at the leading edge of migrating cells where Rho in fact is either inactivated or disintegrated.
  • Rho associates with its effector Rho kinase, Pak-1.
  • the kinase activity of Pak-1 is enhanced when it engages Rac in its GTP "activated" form.
  • the tumor suppressor protein p27 kip binds with its amino- terminal region (N) to complexes of cyclins and cyclin-dependent kinases (CDKs), thus inhibiting cell proliferation.
  • N amino- terminal region
  • CDKs cyclin-dependent kinases
  • P phosphorylated
  • p27 kip 1 is believed to move into the cytoplasm, where as shown by Besson et ciL, it binds through its carboxy terminus (C) to RhoA and interfaces with RhoA activation by guanine-nucleotide-exchange factors (GEFs).
  • RhoA, Cdc42, and Rac regulate the cytoskeletal changes required for cell migration.
  • RhoA through the ROCK protein, works mainly at the rear, determining (among other processes) the turnover of adhesive sites known as focal adhesions and thereby rear retraction.
  • FAK inhibits or promotes cell migration, depending on the cell type.
  • the migration of progenitor dental pulp cells can be controlled by a balance in Rac/Rho-kinase activation.
  • Rac When Rac is activated the cell migrates forward, when Rho-kinase is activated the cell remains fixed in position.
  • drug therapies can be targeted and delivered to the Rho family of GTPases in order to control progenitor dental pulp cell migration as part of tissue engineering therapy described herein.
  • the survival, death, attachment, and proliferation of pulp stem cells and other types of progenitor cells including periodontal stem cells can be used to test biocompatibility and cytotoxicity of the scaffolds, files/cleaning instruments, biomaterials, disinfectants, and medicaments to be used as part of regenerative endodontic treatment described herein. Prior to in vivo clinical or animal testing, these procedures can be tested using in vitro extracted teeth and cell culture techniques or assays.
  • the efficacy of regenerated tissues within the root canal of in vivo teeth can be measured using non-invasive methods such as Doppler measurements of blood flow and electrical pulp vitality testing.
  • non-invasive methods such as Doppler measurements of blood flow and electrical pulp vitality testing.
  • patients can be asked to rate the success of the treatment based on qualitative or quantitative characteristics of interested to the researchers.
  • the teeth may also be extracted for assessment of tissue regeneration associated with the revascualrized root canals.
  • extracted teeth may be subject to various aspects of endodontic tissue regeneration to measure the in vitro efficacy of the regenerative endodontic procedures prior to their clinical or animal testing.
  • the measurement methods include cell survival assays, as well as adherence to root canal surfaces, using scanning/transmission electron microscopy, and histology.
  • kits for use in the methods described herein as well as for use in other suitable dental applications.
  • the kits can include any of the example components described as part of the above methods as well as those components described to follow.
  • the scaffold (also referred to herein as an "implantable matrix”) may be included in a kit that allows a practitioner to deliver comprehensive regenerative endodontic treatment.
  • kits can further comprise any or all of the following: disinfecting solution, isolated dental pulp cells, or endodontic files.
  • the kit can, for example, have a scaffold, manual and/or motorized endodontic files, an irrigating/disinfecting solution and an acid/chelating agent is utilized to clean the necrotic pulp tissues and to disinfect the root canal.
  • the implantable matrix in the kit can be a hydrogel packaged for use in the methods described herein.
  • the implantable matrix in the kit can be composed at least partially of any of the following materials: collagen, fibrin, chitosan, glycosaminoglycans, and mixtures thereof.
  • the implantable matrix in the kit can be •composed at least partially of any of the following materials: polylactic acid, polyglycolic acid, polycaprolactone, and mixtures thereof.
  • the implantable matrix in the kit can be composed at least partially of platelet rich plasma, blood, or any blood serum product.
  • the kit contains an antibiotic.
  • the antibiotic can be, for example, part of the implantable matrix or separately packaged within the kit.
  • the kit contains stem cells or other isolated dental pulp cells. These cells can, in some embodiments, express at least one of the following: von Willebrand factor CD 146, alpha-smooth muscle actin, and 3G5 proteins.
  • kits of the present invention can also contain a cellular growth factor selected from the group consisting of a member of the transforming growth factor-beta family, a bone morphogenic protein, insulin-like growth factor-I or -II, Colony stimulating factor, Epidermal growth factor, Fibroblast growth factor, Insulin-like growth factor-I or II, Interleukins IL-I to IL-13, Platelet-derived growth factor, and Nerve growth factor.
  • a cellular growth factor selected from the group consisting of a member of the transforming growth factor-beta family, a bone morphogenic protein, insulin-like growth factor-I or -II, Colony stimulating factor, Epidermal growth factor, Fibroblast growth factor, Insulin-like growth factor-I or II, Interleukins IL-I to IL-13, Platelet-derived growth factor, and Nerve growth factor.
  • the teeth are disinfected by submerging them in 6% NaOCl (Clorox,
  • HBSS Hanks Balanced Salt Solution
  • Progenitor dental pulp cells are cells are obtained from human exfoliated deciduous (SHED) teeth collected from volunteer patients and frozen prior to use. The cells are cultured in Dulbeccos Modified Eagles Medium (DMEM, BD Biosciences, Franklin Lakes, NJ). Cell cultures are maintained at 37°C in a humidified atmosphere of 5% CO 2 with the culture media being replenished every second day for up to 60 days. Confluent cell cultures are collected by trypsinization (0.25% trypsin/EDTA, Mediatech, Inc., Herndon, VA).
  • DMEM Dulbeccos Modified Eagles Medium
  • OPLA Open-cell polylactic acid
  • Calcium phosphate calcium phosphate
  • collagen scaffolds created from bovine hide bovine hide
  • PBS neutral phosphate buffered saline
  • the first two treatments groups are controls.
  • Group 1 comprising cleaned and shaped root canals without any scaffolds or cells, and
  • Group 2 comprising SHEDxIO 6 injected into the cleaned and shaped root canals of fifteen teeth without any scaffold.
  • the remaining groups comprised the experimental treatment groups.
  • Group 3 comprising the OPLA scaffold is incubated at 37 0 C for 30 minutes before application of the cells to equalize :the culture conditions.
  • Dental pulp constructs are created by seeding SHED xlO 6 in each of OPLA scaffolds using a sterile micro-syringe, twenty four hours prior to implantation.
  • the constructs are then implanted into the root canals of fifteen cleaned and shaped teeth using sterile forceps and endodontic pluggers (Miltex Inc., York, PA).
  • Group 4 comprising the same scaffold as Group 3, except the scaffolds are manufactured from bovine collagen.
  • Group 5, comprising the same scaffold as Group 3, except the scaffolds are manufactured from Calcium phosphate.
  • Group 6, comprising the same scaffold as Group 3, except that 50 ng of BMP-2 is added to each scaffold in 50 ⁇ l of 0.1% Bovine serum albumin (BSA) in PBS pH 7.4.
  • Group 7, comprising the same scaffold as Group 3, except that 50 ng of TGF- ⁇ l (Sigma-Aldrich, St Louis, MO), is added to each scaffold in 50 ⁇ l of 0.1% BSA in PBS pH 7.4.
  • Group 8 comprising the same scaffold as Group 3, except that 50 ng ofl3- glycerophosphate is added to each scaffold in 50 ⁇ l of 0.1% BSA in PBS pH 7.4. All the teeth containing cells, scaffolds and dental pulp constructs are submerged in 1 ml of DMEM culture media and maintained in 24-well culture plates (BD Biosciences, Bedford, MA) for 1 , 7, or 14 days. [0081 ] Preparation for Scanning Electron Microscopy
  • the teeth are fixed by submerging them in a 10% neutral-buffered formalin solution at 18°C for 24 hours.
  • the teeth are then postfixed in osmium tetroxide (l%v/v) for 2 hours before being dehydrated in a graded series of ethanol solutions; 80%, 90%, 95% for 15 minutes each, followed by 3x 10 minutes of 100% ethanol.
  • the teeth are removed from the solutions and placed in hexamethyldistilazane for 5 minutes to fix the dehydrated specimens.
  • the teeth are prepared for visualization in the scanning electron microscope (SEM) by fracturing them into two-halves along the longitudinal axis using a chisel.
  • the teeth are dried on filter paper for 30 minutes.
  • SEM scanning electron microscope
  • the tooth specimens are mounted onto aluminum stereoscan stubs with rapid set Araldite (Devcon Ltd, Shannon, Ireland).
  • the dried mounted specimens are coated with a 20- 30nm thin metallic layer of gold/palladium in a Cressington Sputter Coater model 108Auto (Watford, U.K.)
  • the specimens are viewed in a Quanta 200 SEM (FEI, Hilsboro, OR). SEM micrographs are obtained at x2,000 magnification using digital image analysis software. Each of the root canals is scanned in its entirety to obtain an overview of the general surface topography. Cell attachment is visualized within the dental pulp constructs and to root canal dentin using micrographs. The effectiveness of the tissue engineered dental pulp constructs to adhere to the root canals is assessed using semi-quantitative criteria.
  • the non-human primate was sacrificed and the teeth were processed for histology, and the teeth were viewed under a light microscope x200.
  • the collagen scaffolds attracted the most white blood cells into the root canal spaces, and the cells had an even distribution.
  • the Pl 5 - Pepgen bone regeneration material attracted fewer white blood cells In the Pl 5 - Pepgen is a solid granular material with a gel binder; however, the white blood cells were on the periphery not within the scaffold. By comparison the blood clot had the fewest cells in the root canals.
  • Routine endodontic root canal therapy was performed on all the anterior and premolar (palatal canal) and molar (palatal canal) teeth of one M. fascicularis non-human primate aged approximately 7 years of age. The animal was given general anesthesia during surgery and analgesics following surgery to minimize and pain or stress associated with the dental procedures.
  • the M. fascicularis non-human primate was anesthetized with 10-15 mg/kg ketamine and maintained with isoflurane at a concentration of 1.5%.
  • the monkey was intubated during the dental procedures.
  • the heart rate, respiratory rate and toe pinch reflex (deep pain assessment) were monitored during the procedures.
  • the non-human primate teeth were treated according to the same procedures commonly applied in clinical dental practice. Each tooth was radiographed for a comparison of pre-treated versus post-treated changes in the root canal. A rubber dam anchored with rubber dam clamps was used and the surgical field was disinfected with 2% clorohexidine. A dental hand piece was used to cut a pulp chamber access cavity in the crown of each tooth. A water-spray was used to cool the tooth during access cavity cutting.
  • the tooth apex was instrumented using #15 K- file to cause bleeding into the cleaned root canal system.
  • Table 1 the teeth were randomly divided into the three different treatment groups: 1.
  • the scaffolds or blood clots in each of the treatment groups had 4mm of MTA placed as a biocompatible base, prior to final restoration with a self-cure glass ionomer (Fuji II, GC, Tokyo, Japan).
  • the harvested tissues were processed for light microscope histology.
  • the extracted teeth were fixed with 4% paraformaldehyde for 24 hours and demineralized using demineralizing solution (VWR Sewane, GA). After washing, the teeth were dehydrated in a graded series of alcohols (70%, 80%, 90%, 95% for two hours each), followed by two hours of 100% ethanol and then embedded in paraffin wax blocks and cut into 5 micron slices with a microtome.
  • the histological slices of teeth were collected on glass slides and maintained at 65 0 C for 12 hours.
  • the slides were stained with hematoxylin and eosin stain using the following protocol: Xylene (3 minutes), xylene and 100% alcohol (50/50, dip), 95% ethanol (3 minutes), 70% methanol (1 minute), water (1 minute), hematoxylin (2 minutes), running water (dip), acid alcohol (dip), water (dip), 13% ammonia (dip), running water (5 minutes), 80% ethanol (dip), eosin (15 seconds), 95% ethanol (3 dips), 100% ethanol (3 minutes), and xylene (1 minute or until fixed on slides).
  • the tissues were sealed onto the glass slides with cover-slips applied with Sure-Mount adhesive (Triangle Biomedical Sciences, Durham, NC).

Landscapes

  • Health & Medical Sciences (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)

Abstract

La présente invention concerne de nouveaux procédés et coffrets permettant de retirer un tissu de pulpe dentaire non sain ou nécrotique de l'intérieur des canaux radiculaires d'une dent, et de le remplacer par un nouveau tissu vascularisé créé par un traitement endodontique régénératif. La présente invention offre des alternatives aux thérapies courantes de canal radiculaire, ainsi qu'à l'obturation du canal radiculaire par des matériaux dentaires.
EP08861918.4A 2007-12-14 2008-12-12 Procédé et trousse permettant d'administrer un traitement endodontique régénératif Withdrawn EP2268254A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1382107P 2007-12-14 2007-12-14
PCT/US2008/013699 WO2009078971A1 (fr) 2007-12-14 2008-12-12 Procédé et trousse permettant d'administrer un traitement endodontique régénératif

Publications (2)

Publication Number Publication Date
EP2268254A1 true EP2268254A1 (fr) 2011-01-05
EP2268254A4 EP2268254A4 (fr) 2013-12-11

Family

ID=40795824

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08861918.4A Withdrawn EP2268254A4 (fr) 2007-12-14 2008-12-12 Procédé et trousse permettant d'administrer un traitement endodontique régénératif

Country Status (5)

Country Link
EP (1) EP2268254A4 (fr)
JP (1) JP2011505970A (fr)
KR (1) KR20100103821A (fr)
CA (1) CA2710206A1 (fr)
WO (1) WO2009078971A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019183201A1 (fr) * 2018-03-20 2019-09-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Régénération de la pulpe dentaire vitale

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101970022A (zh) * 2008-03-12 2011-02-09 财团法人日本健康科学振兴财团 根管填充材料以及牙组织再生方法
EP2476442B1 (fr) * 2009-09-11 2019-04-17 National Center for Geriatrics and Gerontology Obturateur de canal radiculaire pour dent non extraite et procédé d'extraction destiné à la régénération du tissu dentaire
JP2011177140A (ja) * 2010-03-03 2011-09-15 Nippon Dental Univ 幹細胞培養用の無血清培地
US20110256495A1 (en) * 2010-04-15 2011-10-20 University Of Southern California Methods and related kits for treating and regenerating tooth pulp and periapical tissues in a mammal
US9180072B2 (en) * 2010-06-16 2015-11-10 Department Of Biotechnology Sealbio: a novel non-obturation regenerative technique of endodontic treatment
WO2012012507A2 (fr) * 2010-07-23 2012-01-26 Biomatrx Llc Procédés, inserts, et systèmes utiles pour traitement endodontique
JP5939559B2 (ja) * 2011-02-28 2016-06-22 国立研究開発法人国立長寿医療研究センター 間葉系幹細胞を含んでなる根管充填材、及びこれを用いた歯組織再生方法
EP3446723B1 (fr) * 2016-03-31 2023-04-12 National Center for Geriatrics and Gerontology Matériau de prétraitement dentaire et trousse de régénération de tissu dentaire

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010041324A1 (en) * 1995-06-06 2001-11-15 Ultradent Products, Inc. Endodontic systems and methods for preparing upper portions of root canals with increasingly rigid files
US20030235804A1 (en) * 2002-01-23 2003-12-25 Mahmoud Torabinejad Irrigation solution and methods for use
US20040058442A1 (en) * 2000-07-21 2004-03-25 Songtao Shi Adult human dental pulp stem cells in vitro and in vivo
WO2006116530A2 (fr) * 2005-04-28 2006-11-02 The Trustees Of Columbia University In The City Of New York Compositions et procedes pour traiter des inflammations pulpaires induites par infection ou par traumatisme
US20070248933A1 (en) * 2003-10-10 2007-10-25 Dentigenix Inc. Methods for treating dental conditions using tissue scaffolds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040193274A1 (en) * 2003-03-28 2004-09-30 Trieu Hai H. Materials and methods for augmenting and/or repairing intervertebral discs
US6968229B2 (en) * 2003-05-06 2005-11-22 Ormco Corporation Apex locating system
JP4915004B2 (ja) * 2004-03-22 2012-04-11 公益財団法人新産業創造研究機構 生分解性樹脂複合材料により構成される組織再生用足場（スカフォールド）
JP2005341961A (ja) * 2004-05-07 2005-12-15 Hitachi Medical Corp ヒト歯髄細胞の分化誘導方法及び象牙質再生用組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010041324A1 (en) * 1995-06-06 2001-11-15 Ultradent Products, Inc. Endodontic systems and methods for preparing upper portions of root canals with increasingly rigid files
US20040058442A1 (en) * 2000-07-21 2004-03-25 Songtao Shi Adult human dental pulp stem cells in vitro and in vivo
US20030235804A1 (en) * 2002-01-23 2003-12-25 Mahmoud Torabinejad Irrigation solution and methods for use
US20070248933A1 (en) * 2003-10-10 2007-10-25 Dentigenix Inc. Methods for treating dental conditions using tissue scaffolds
WO2006116530A2 (fr) * 2005-04-28 2006-11-02 The Trustees Of Columbia University In The City Of New York Compositions et procedes pour traiter des inflammations pulpaires induites par infection ou par traumatisme

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BANCHS ET AL: "Revascularization of Immature Permanent Teeth With Apical Periodontitis: New Treatment Protocol?", JOURNAL OF ENDODONTICS, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, PA, US, vol. 30, no. 4, 1 April 2004 (2004-04-01), pages 196-200, XP005354446, ISSN: 0099-2399, DOI: 10.1097/00004770-200404000-00003 *
MURRAY ET AL: "Regenerative Endodontics: A Review of Current Status and a Call for Action", JOURNAL OF ENDODONTICS, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, PA, US, vol. 33, no. 4, 16 March 2007 (2007-03-16) , pages 377-390, XP005939431, ISSN: 0099-2399, DOI: 10.1016/J.JOEN.2006.09.013 *
See also references of WO2009078971A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019183201A1 (fr) * 2018-03-20 2019-09-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Régénération de la pulpe dentaire vitale

Also Published As

Publication number Publication date
WO2009078971A1 (fr) 2009-06-25
EP2268254A4 (fr) 2013-12-11
KR20100103821A (ko) 2010-09-28
CA2710206A1 (fr) 2009-06-25
JP2011505970A (ja) 2011-03-03

Similar Documents

Publication Publication Date Title
US20100203481A1 (en) Method and kit for delivering endodontic regenerative treatment
Raddall et al. Biomaterials and scaffold design strategies for regenerative endodontic therapy
Gotlieb et al. An ultrastructural investigation of tissue-engineered pulp constructs implanted within endodontically treated teeth
WO2009078971A1 (fr) Procédé et trousse permettant d'administrer un traitement endodontique régénératif
US6899915B2 (en) Methods and compositions for culturing a biological tooth
EP2263706B1 (fr) Matière de remplissage de canal radiculaire et procédé de régénération de tissu dentaire
El Ashiry et al. Tissue engineering of necrotic dental pulp of immature teeth with apical periodontitis in dogs: radiographic and histological evaluation
Orti et al. Pulp regeneration concepts for nonvital teeth: from tissue engineering to clinical approaches
US20090148486A1 (en) Compositions and methods for treating pulp inflammations caused by infection or trauma
Chandrahasa et al. Proliferation of mature ex vivo human dental pulp using tissue engineering scaffolds
Liu et al. Biomaterial scaffolds for clinical procedures in endodontic regeneration
WO2006116530A2 (fr) Compositions et procedes pour traiter des inflammations pulpaires induites par infection ou par traumatisme
US20190015551A1 (en) Construct for preventing immunological rejection generated when used in transplants, and method for using collagen in a gel state, in the form of dry lyophilised spongy mouldings and 3d matrices
Grawish et al. Challenges of engineering biomimetic dental and paradental tissues
Tan et al. Regeneration of dentin–pulp-like tissue using an injectable tissue engineering technique
Palit et al. Tissue engineering in endodontics: root canal revascularization
Karpyuk et al. Innovation-based approach in reconstruction of reduced jaw alveolar ridge bone using cell regeneration technologies
US20130166040A1 (en) Reagents and methods for preparing teeth for implantation
Astudillo-Ortiz et al. Endodontic tissue regeneration: a review for tissue engineers and dentists
RU2605630C1 (ru) Способ аутотрансплантации зуба с сохранением жизнеспособности его пульпы
RU2368338C1 (ru) Способ восстановления тканей пародонта
Hatab et al. In vivo and immunohistochemical study of dentin and pulp tissue regeneration in the root canal
Kumar et al. Regenerative endodontics
Aggarwal et al. Regenerative Endodontics-Potential Approaches in Revitalizing the Tooth Pulp-A Review Article
RU40885U1 (ru) Материал для имплантации в ткани пародонта

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100715

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: GARCIA-GODOY, FRANKLIN

Inventor name: MURRAY, PETER E.

A4 Supplementary search report drawn up and despatched

Effective date: 20131108

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 6/00 20060101AFI20131104BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140607